Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ: VRTX )

350.54 -1.15 (-0.33%)
Streaming Delayed Price Updated: 3:01 PM EDT, Sep 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Vertex Pharmaceuticals

< Previous 1 2 3 4 Next >
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Inc. (VRTX) Climbs to Annual-High Share Price
Via Investor Brand Network
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Vertex Pharmaceuticals Incorporated with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Vertex Pharmaceuticals Incorporated with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Vertex Pharmaceuticals Incorporated Investors with Losses to Inquire About Class Action Investigation – VRTX
From The Rosen Law Firm, P.A.
Via Business Wire
Suketu Upadhyay Elected to Vertex Board of Directors
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey Leiden Center for Cell and Genetic Therapies
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants
From Vertex Pharmaceuticals
Via Business Wire
Vertex Reports First Quarter 2022 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Announce First Quarter 2022 Financial Results on May 5
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 Through 11 years With At Least One F508del Mutation
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Inc. (VRTX) Climbs to Annual-High Share Price
Via Investor Brand Network
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for Patients With Cystic Fibrosis Ages 12 Years and Older With at Least One F508del Mutation in the CFTR Gene
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
From Vertex Pharmaceuticals Incorporated
Via Business Wire
European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal Segmental Glomerulosclerosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis 12 Years and Older With At Least One F508del Mutation in the CFTR Gene
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor in Children With Cystic Fibrosis Ages 6 Through 11
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Reports Third-Quarter 2021 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
From Mammoth Biosciences
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.